Background: Interactions between principal cytotoxic thiopurine metabolites, that is 6-thioguanine nucleotides , and infliximab [IFX] and anti-IFX antibodies [Abs] may contribute to higher effectiveness of IFX-thiopurine combination therapy than monotherapies in inflammatory bowel disease. Methods: To examine if thiopurine metabolites influenced trough IFX and anti-IFX Abs, 89 patients previously assessed for anti-IFX Abs were included. To assess if IFX influenced thiopurine metabolites, eight patients who had responded to 12 weeks of intensified IFX at a constant thiopurine dosing were included. Conclusions: Superior effect of IFX-thiopurine combination therapy over monotherapies partly relates to decrease in anti-IFX Abs, which associates with 6-TGN levels and has a lower therapeutic threshold than during thiopurine monotherapy. Additional benefit likely ascribes to synergy between different anti-inflammatory modes of action rather than direct drug interactions.
Introduction
Patients with inflammatory bowel disease [IBD] usually need antiinflammatory treatment, and tumour necrosis factor [TNF] inhibitors such as infliximab [IFX] are a cornerstone in the therapeutic armentarium. 1 Unfortunately, up to half of patients lose the effect of IFX maintenance therapy. 2 This can be caused by formation of antibodies against IFX [anti-IFX Abs] leading to decreased or absent circulating levels of active drug. 3 Continued IFX therapy in the presence of anti-IFX Abs can also result in severe hypersensitivity reactions. 4 Patients who develop anti-IFX Abs are prone to later develop anti-adalimumab Abs, leading to repeat loss of response. 5 Thus, it is pertinent to find ways to minimise the risk of anti-IFX Ab formation.
Previous studies have convincingly shown that combination therapy with IFX and thiopurines is more effective than monotherapy with either agent in immunosuppressor-naïve IBD patients. [6] [7] [8] Whereas TNF inhibitors are large-molecular weight monoclonal antibodies that target the pro-inflammatory cytokines, TNF-α, thiopurines (i.e. 6-mercaptopurine and its pro-drug, azathioprine [AZA]), are small-molecular drugs that undergo complex enzymatic metabolism with formation of both therapeutic active and inactive metabolites. 9 The primary immunosuppressive metabolites are 6-thioguanine nucleotides , which are incorporated into DNA and RNA and thereby induce apoptosis in, for example, lymphocytes. 10 The mechanism for improved effectiveness of IFXthiopurine combination treatment over monotherapies has been hypothesised to originate from thiopurines' decreasing immunogenicity of IFX or, alternatively, that thiopurines directly influence circulating IFX levels. 11 It has relatively consistently been observed that fewer patients receiving combination therapy have detectable anti-IFX Abs 6, 8, 11, 12 ─and it was recently reported that 6-TGN associated with anti-IFX Abs. 11 The primary aim of this study was to investigate the interplay between principal cytotoxic thiopurine metabolites (6-TGN and methylated mercaptopurine metabolites ) and IFX and anti-IFX Abs. Furthermore, we aimed to to establish thresholds for thiopurine metabolites that associate with improved pharmacokinetics of IFX or less likelihood of anti-IFX Abs.
Methods

Study design
2.1.1. Influence of thiopurine metabolites on infliximab and anti-infliximab antibodies The first part was a retrospective cohort study that examined if thiopurine metabolites associate with trough IFX levels and anti-IFX Abs. The study population comprised all patients treated with IFX at our tertiary IBD centre since 2009, in whom IFX and anti-IFX Abs had been assessed [at the discretion of the treating physician until 2012 and hereafter at predefined time points according to local guidelines: after 1 year of treatment and then at every 6 months─or at any time of suspected treatment failure]. The two principal cytotoxic cytosolic thiopurine metabolites, 6-TGN and 6-MeMP, were determined in red blood cells [RBC] in stored samples at time points corresponding exactly to those when IFX and anti-IFX Abs had been measured. We included patients who had received IFX induction treatment and at least one maintenance infusion. Patients who received concomitant thiopurines [AZA or 6-MP] were included only if they had received a stable dose for at least 2 months before sampling, in order to allow for thiopurine metabolites to achieve steady-state erythrocyte concentrations. 13 Patients were excluded if they received systemic steroid treatment > 5 mg/day, allopurinol, methotrexate, or ciclosporin. This study was approved by the Danish Health and Medical Authority [H-15018092] and the Danish Data Protection Agency [HGH-2016-019:04434].
Influence of infliximab on thiopurine metabolites
The second part of the study was a post-hoc analysis of data from a randomised controlled trial, and examined if IFX influences the concentration of thiopurine metabolites. The study population comprised eight Crohn's disease patients with active luminal disease despite standard IFX maintenance therapy. These patients had received an intensified IFX regimen comprising 5 mg/kg every 4 weeks for a total of 12 weeks, during which all eight patients had a clinical response (Crohn's Disease Activity Index [CDAI] decrease of ≥70). 14 . [16] [17] [18] All analyses were done by a commercial provider under blinded conditions [Euro Diagnostica, SE; formerly Biomonitor A/S, DK]. In the event that a patient had both a positive and a negative anti-IFX Ab test at different time points, the positive sample and the corresponding IFX trough level were used. The most recent sample was used if more than one negative anti-IFX Ab test was available.
2.2.2.
Thiopurine metabolites RBC concentrations of 6-TGN and 6-MeMP metabolites were determined in biobanked buffy-coat samples [stored at -80°C] which had all been collected exactly at the day of IFX and anti-IFX Ab measurements. Quantification was carried out by hot acid hydrolysis followed by ultra-performance liquid chromatography, as previously described. [19] [20] [21] 
Statistics
Descriptive data were presented as percentages for discrete variables, and as median with interquartile range [IQR] Figure 2A ]. This association persisted in both univariate and multivariate logistic regression models [ Table 2 ]. ROC analysis also revealed a significant difference in 6-TGN be- Figure 3B ]. Lack of associations between IFX and multiple study variables, including thipurine metabolites, were also found in both univariate and multiple regression models [ Table 3 ]. The frequency of IFX infusions was, however, expectedly associated with IFX trough levels. 
Influence of IFX on thiopurine metabolites
Study population
The study population comprised eight patients with Crohn's disease who all had manifest treatment failure of IFX maintenance therapy at time of inclusion, with response to 12 weeks of intensified IFX therapy at a constant thiopurine dosing throughout 20 weeks [ Table 4 ].
Influence of infliximab on thiopurine metabolites
As expected, circulating trough IFX levels increased substantially during the 12-week period of IFX intensification in the parent trial [ΔIFX 
Discussion
In the first part of this study, we initially observed that significantly fewer patients receiving IFX-thiopurine combination treatment had detectable anti-IFX Abs as compared with those receiving monotherapy. This is consistent with previous pivotal randomised controlled trials. [6] [7] [8] To further explore this finding, we measured thiopurine metabolite levels and found that 6-TGN levels were substantially lower in IFX Ab-positive than in IFX Ab-negative patients. This observation is congruent with another recently published observation. 11 The association between 6-TGN and anti-IFX Abs in two independent cohort studies calls for studies to unravel the precise underlying mechanisms for this observation. We also examined whether circulating trough IFX levels themselves were directly associated with 6-TGN levels independently of anti-IFX Ab formation. In our study, IFX and thiopurine metabolite levels were measured at matched time points, but no such association was found. This observation contrasts with a previous reporting of a moderate positive correlation between IFX and 6-TGN levels. 11 However, in that study the correlation analysis was carried out in unselected patients receiving thiopurines rather than in the more relevant anti-IFX Absnegative subset, as we did. Hence, we believe that it is essential to exclude the potentially confounding effect of anti-IFX Abs to ensure that the correlation is in fact related to 6-TGN. Taken together, our findings are in keeping with the known superior clinical efficacy of combination therapy with IFX and thiopurines over monotherapies, and support therapeutic drug monitoring to optimise 6-TGN levels in order to minimise risk of anti-IFX Abs. [6] [7] [8] As mentioned above, several studies now support the view that combination treatment with thiopurines and IFX results in lower risk of anti-IFX Abs than IFX monotherapy. However, only approximately 20% of patients receiving IFX actually develop anti-IFX Abs, indicating that other mechanisms may contribute to the overall additive effect of combination treatment. 22 These mechanisms are not well understood, but our data support that 6-TGN does not directly associate with circulating IFX levels. Moreover, in the second part of the study we observed that the opposite mechanism did not appear operative, as 6-TGN levels remained stable in a setting of highly increased IFX exposure in an otherwise homogeneous population receiving steady thiopurine dosing. A previous study of 32 patients reported a temporary increase of 6-TGN levels 1-3 weeks after an IFX infusion [non-trough] in patients receiving steady azathioprine therapy, but with 6-TGN having dropped to pre-infusion levels at time of next scheduled infusion [trough] . 23 We believe that our study provides useful data on these interactions, as IFX levels and 6-TGN levels were examined in two different scenarios with either a steady [part 1] or an intensified [part 2] dose of IFX and showed no association between IFX levels and 6-TGN levels or vice versa. Taken together, it seems likely that the improved efficacy of the combination treatment, beyond reducing risk of anti-IFX Abs, reflects that thiopurines and IFX have different anti-inflammatory mechanisms of action and therefore act synergistically to reduce the inflammatory load more effectively when given in combination─rather than through direct drug interactions. 24, 25 The findings of the present study have clinical perspectives. Thiopurines are associated with a well-known panel of side effects such as nausea, vomiting, and flu-like symptoms as well as hepatotoxicity and bone marrow depression. These side effects may be reduced or eliminated by shifting to low-dose thiopurine-allopurinol combination treatment in patients who predominantly shunt the drug to 6-MeMP rather than 6-TGN, but this is not always feasible, and some patients tolerate only lower doses. For those also receiving IFX, it is essential to reduce immunogenicity, and the ROC analysis of our data shows that no patients with a 6-TGN level of ≥117 pmol/8 × 10
8 RBC had detectable anti-IFX Abs. Interestingly, this figure is very close to that reported by another group where patients with 6-TGN < 125 pmol/8 × 10 8 RBC had higher risk of developing anti-IFX Abs. 11 It has been proposed that a 6-TGN threshold of 230-260 pmol/8 × 10 8 RBCs in patients on thiopurine monotherapy is best correlated to clinical remission. 22, 26 However, taking into account the present findings, an even lower threshold of ~120 pmol/8 × 10 8 RBC seems to be sufficient to reduce risk of anti-IFX Abs in patients receiving IFX-thiopurine combination therapy. This favours use of lower thiopurine doses during combination therpay─especially in patients intolerant to standard weight-based thiopurine dosing. Our study along with others shows that 6-MeMP does not influence anti-IFX Abs or circulating IFX, thus supporting use of allopurinol to shunt thiopurine metabolism in the direction of 6-TGN. [9] [10] [11] The major limitations in cohort 1 are the retrospective observational design including inherent restrictions regarding causality, and that testing was neither completely standardised nor predefined, introducing risk of selection bias. As the objective was to explore potential drug interactions between thiopurine metabolites and IFX, treatment outcomes were not assessed and data from patients with Crohn's disease and ulcerative colitis were pooled to yield power [cohort 1]. However, the majority of patients had surprisingly low 6-TGN levels, thus warranting caution when extrapolating the results. Even though we cannot rule out that lack of association between 6-TGN and IFX in cohort 1 was due confounders, the multiple regression analysis did not indicate that this was the case; and it was not apparent that patients receiving IFX-thiopurine combination therapy had a markedly more severe disease course than those receiving IFX monotherapy [ Table 1 ]. The use in cohort 1 of different analytical techniques across time, due to changes in technology by the supplier company, is unlikely to have had major implications in IFX quantifications as the IFX assays have been shown to correlate well. 16, 17 Bias may, however, have been introduced regarding anti-IFX Ab detection, as assays are less congruent and have different drug sensitivity [RIA has moderate drug sensitivity; 18, 27 EIA is not prone to drug interference; 16, 18 RGA is a a cell-based assay which measures the functional activity of drug and anti-drug Abs at the cellular TNF receptor level, thus rendering it sensitive to IFX [> ~0.65 µg/mL] ─only samples without detectable IFX by RGA were assessed for anti-IFX Abs by RGA, whereas samples with detectable IFX were generally tested for anti-IFX Abs by EIA to accommodate for potential drug interference. 17 As thiopurines [AZA and 6-MP] were handed out in our clinic to the patients, adherence is likely to be high although non-adherence in patients with low thiopurine metabolite levels cannot completely be ruled out. Although cohort 2 was very small, our observations add weight to lack of influence of IFX on thiopurine metabolite levels, because the cohort consisted of a highly homogeneous population receiving a steady thiopurine dosing with repeated standardised measurements of thiopurine metabolites and IFX and anti-IFX Abs across time, and with the only variable changed being the increased exposure of IFX.
In conclusion, superior effectiveness of IFX-thiopurine combination therapy in part relates to decreased anti-IFX Abs. Importantly, this effect seems to be influenced by 6-TGN and, with a relatively low 6-TGN threshold of ≥ ~120 pmol/8 × 10 8 RBC, to substantially reduce or completely eliminate risk of anti-IFX Abs. Additional benefit from IFX-thiopurine combination therapy over monotherapies appears related to synergy between different antiinflammatory modes of action rather than to direct interactions between thiopurine metabolites and IFX or vice versa. The results support the view that therapeutic drug monitoring can be implemented during thiopurine-IFX combination treatment to optimise 6-TGN levels and lower 6-MeMP levels, in order to improve efficacy and reduce risk of side effects. For those patients who only tolerate lower doses, a 6-TGN level of about 120 pmol/8 × 10 8 RBC as of now seems to be a sound target threshold during combination therapy.
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